Abstract. There is unmet need for prediction of treatment response for chronic myeloid leukemia (CML) patients. The present study aims to identify disease-specific/diseaseassociated protein biomarkers detectable in bone marrow and peripheral blood for objective prediction of individual's best treatment options and prognostic monitoring of CML patients. Bone marrow plasma (BMP) and peripheral blood plasma (PBP) samples from newly-diagnosed chronic-phase CML patients were subjected to expression-proteomics using quantitative two-dimensional gel electrophoresis (2-DE) and label-free liquid chromatography tandem mass spectrometry (LC-MS/MS). Analysis of 2-DE protein fingerprints preceding therapy commencement accurately predicts 13 individuals that achieved major molecular response (MMR) at 6 months from 12 subjects without MMR (No-MMR). Results were independently validated using LC-MS/MS analysis of BMP and PBP from patients that have more than 24 months followed-up. One hundred and sixty-four and 138 proteins with significant differential expression profiles were identified from PBP and BMP, respectively and only 54 proteins overlap between the two datasets. The protein panels also discriminates accurately patients that stay on imatinib treatment from patients ultimately needing alternative treatment. Among the identified proteins are TYRO3, a member of TAM family of receptor tyrosine kinases (RTKs), the S100A8, and MYC and all of which have been implicated in CML. Our findings indicate analyses of a panel of protein signatures is capable of objective prediction of molecular response and therapy choice for CML patients at diagnosis as 'personalized-medicine-model'.
Introduction
Chronic myeloid leukemia (CML) is unequivocally distinguishable from other myeloproliferative disorders by the presence of a reciprocal translocation of chromosomes 9 and 22 (1) (2) (3) . Although the Philadelphia chromosome is detected in 90-95% of CML patients, evidence of the BCR-ABL rearrangement is also usually detected in the subgroup of Philadelphia chromosome-negative CML patients (4) (5) (6) .
The presence of BCR-ABL in CML patients and the requirement of kinase activity for BCR-ABL function make this an attractive target for selective kinase inhibitors.
The old traditional therapy of newly diagnosed chronic phase-CML patients includes busulfan and hydroxyurea and most of the patients will stay in a chronic phase for approximately 3-5 years (7, 8) . Treatment of CML later evolved to where the goal was prolongation of the chronic phase through induction of karyotypic remission and possibly molecular remission using Alfa-interferon therapy with or without cyto-sine arabinoside. Thereafter, imatinib mesylate (IM) a tyrosine kinase inhibitor (TKI) was introduced as potential molecular therapy for CML (7, 9) . IM is capable of inhibiting BCR-ABL kinase activity by blocking ABL tyrosine kinase action through the binding and subsequent inactivation of the ATP-binding sites of ABL tyrosine kinase in leukemic cells (9, 10) . Since its introduction, several clinical trials have demonstrated the efficacy of IM and new generation TKIs in the treatment of CML, including patients with interferon-refractory CP-CML, as well as patients with CML in blast crisis (11) .
Approximately more than 50% of CML patients treated with imatinib achieve a complete cytogenetic response (11, 12) . CML progression while on imatinib is usually due to the emergence of imatinib-resistant BCR-ABL mutant cells.
The relatively unpredictable biological behavior is a major challenge in its management as the chronic phase of CML is less aggressive and has very favorable prognosis with an excellent 5-year survival rate. By contrast, the biologically aggressive blast phase of CML is often rapidly fatal (2) . Currently, there is no recognized prognostic value for the baseline BCR-ABL level, furthermore, there are variations in sensitivity or dependability of RQ-PCR assays across different laboratories (13) . There is therefore a need to develop molecular markers for selection of choice of therapy at the time of diagnosis and to identify patients that are more likely to achieve a sustained remission, and patients who are more likely to develop resistance to imatinib therapy.
New analytical tools in proteomics are emerging that give new insights into biological processes that may speed up the discovery of potential biomarkers. Quantitative molecular variations may be used for the development of methods for tumor classification based on large amounts of gene expression data generated by 2-DE analysis of proteins (14, 15) .
The main aim of the present study is towards discovery of objective markers that predict patients' response status and selection of appropriate choice of therapy at the onset of disease diagnosis. It focuses on the analysis of global peripheral blood plasma and bone marrow plasma protein expression profiles among CP-CML patients who achieved LT-MMR on imatinib compared with patients without MMR as well as whether or not they remain on TKI or switch to second generation TKI or requiring alternative therapy.
The endpoint is to identify disease-specific/disease-associated protein biomarkers seen in bone marrow tissue as well as in peripheral blood plasma. This would subsequently allow monitoring of such biomarker proteins in peripheral blood, rather than bone marrow, demanding less invasive procedures for objective prediction of individual's best treatment options and prognostic monitoring of CML patients.
Materials and methods
All bone marrow samples were obtained by aspiration procedure via posterior iliac crest under local anesthesia. Because of limited amount of materials for analysis, the cells were not flow cytometry sorted, rather unsorted bone marrows as well as unsorted peripheral blood plasma were collected and prepared for analysis.
Bone marrow and plasma, samples obtained at diagnosis and prior to initiation of treatment from 37 patients with newly diagnosed CP-CML were subjected to expression proteome analysis using combined gel-based 2-DE and label-free in-solution quantitative liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Patients selections into those that achieved or did not achieve MMR was based on patients with serial positive or negative responses to treatment at different time-points (3, 6, 12 and 24 months, respectively). Patients that responded at a time-point but failed to respond at the next time-point were not included in the analysis. however, patients that did not achieve MMR at 3 months, but subsequently achieved MMR at 6, 12 and 24 months were included. Because there was fewer number of patients with MMR at 3 months, the focus of our analyzed time-points were at 6, 12 and 24 months. Twenty-five patients consisting 13 with major molecular response and 12 without major molecular response were analyzed. In addition, patients that failed tyrosine kinase inhibitor (TKI) were analyzed. Four additional patients Table I . Clinical characteristics of analyzed samples. MMR at  MMR at  MMR at  TKI-fail  6 months  12 months  18 months  24 months  ------------------------------------------------------------------------------------------------------------------Samples  Gender  Age (years)  No  Yes  No  Yes  No  Yes  No  Yes  No  Yes   CML1  Female  14  √  √  √  √  √  CML2  Female  14  √  √  √  √  √  CML3  Female  26  √  √  √  CML4  Male  18  √  √  √  √  √  CML5  Male  50  √  √  √  √  √  CML6  Female  50  √ Male  18  √  √  √  √  √  CML25  Male  40  √  √  √  √  √  CML26  Female  30  √  √  CML27  Female  36  √  √  √  √  √  CML28  Female  37  √  √  √  √  √  CML29  Female  33  √  √  √  √  √  CML30  Female  44  √  √  √  √  √  CML31  Female  48  CML32  Female  38  √  √  CML33  Female  32  √  √  √  CML34  Male  52  √  √  √  √  √  CML38  Male  37  CML40  Male  61  √  √  √  √  CML41  Male  47  √  √  √  √  √  CML43  Female  51  √  √  √  √  √  CML44  Female  14  √  √  √  √  √  CML45  Female  45  √  √  √  √  √  CML46  Female  45  √  √  √  √  √  CML47  Male  32  √  √  √  √  √  Total  19  16  17  18  16  17  11  20  8  22 samples not included in the proteomics analysis were used in the western blot analysis. The overview of experimental design is shown in Fig. 1 and the clinical characteristics of all patients were as indicated in Table I .
MMR at
Sample preparation protocols for proteomic analysis. All the patients with primary diagnosis of CML were recruited in Oncology Center at KFSh&RC. From each of the patients, 10 ml of peripheral EDTA-anti-coagulated blood (plasma) was taken. where possible, bone marrow aspirations were obtained from the same patients in addition to peripheral blood samples. All samples were subjected to extensive pre-analysis cleanup using human albumin removal protocols (Agilent Technologies). written and signed informed consents were obtained from all patients and the Institution's Research Advisory Council, under the Office of Research Affairs, approved the study (RAC# 2050-040).
Protein separation by high resolution two dimensional gel electrophoresis, (2-DE) scanning and image analysis.
Equivalent amount of 50 mg total proteins for each analyzed sample was dissolved in 350 ml volume of rehydration buffer [2% (v/v) IPG-buffer 4-7 linear] and loaded onto an 11-cm IPG-strip 4-7 linear (Bio-Rad Laboratories). This gave better overview of gel separated protein spots across the entire chosen ph window and gel images were visualized by SYPRO Ruby fluorescent staining. Stained gels were scanned using a Typhoon Trio Imager (GE) and data were analyzed using the Progenesis SameSpots software (version 7.1.0; Nonlinear Dynamics, Ltd., Newcastle, UK). Gel images were compared for qualitative and quantitative differences. In addition, the protein expression profiles were used to assess the level of individual variability and only samples with similar phenotypic changes were used for sample pools for LC/MS/MS (due to low through-put analysis) as detailed below. Polypeptide quantities were calculated based on the normalized total integrated density volume.
Protein in solution-digestion. The plasma samples were diluted and protein concentrations of all samples were normalized as previously described (16) . Briefly, for analytical runs, equal amount of protein was taken from each sample to generate a pool of patient as one group. The samples within same sample cohort were pooled due to low through-put of LC/MS/MS analysis platform. however, samples were initially screened using 2-DE for homogeneity within the same analysis group. For each analysis sample group, 200 µg complex protein mixture was taken and exchanged twice with 500 µl of 0.1% RapiGest (waters Corp., Manchester, UK). Protein concentrations of between 0.50 and 1 µg/µl was achieved at the end of digestion. Details of digestion protocols are as previously described (16, 17) . Briefly, proteins were denatured in 0.1% RapiGest SF at 80˚C for 15 min, reduced in 10 mM DTT at 60˚C for 30 min, and alkylated in 10 mM Iodoacetamide (IAA) for 40 min at room temperature in the dark. Samples were trypsin digested at 37˚C overnight. Samples were diluted with aqueous 0.1% formic acid prior to LC/MS analysis in order to achieve a load of ~2 µg on analytical column. All samples were spiked with yeast alcohol dehydrogenase (ADh; P00330) as internal standard to the digests in order for absolute quantitation.
Protein identification by mass spectrometry: LC-MSE analysis. The digested peptides were subjected to 1-Dimensional Nano Acquity liquid chromatography coupled with tandem mass spectrometry on Synapt G2 (waters Corp.). Expression proteomics data were generated between sample groups using both qualitative and quantitative protein changes. The ESI-MS analysis and instrument settings were optimized on the tune page as previously reported (16) .
A total of 2 µl sample injection representing ~1 µg protein digests was loaded on-column and samples were infused using the Acquity sample manager with mobile phase consisting of A1 99% water +1% acetonitrile + 0.1% formic acid and B1 acetonitrile + 0.1% formic acid with sample flow rate of 0.450 µl/min. Data acquisition using iron mobility separation experiments (hDMSE) were performed and data were acquired over a range of m/z 50-2000 Da with a total acquisition time of 115 min. All samples were analyzed in triplicate runs (triplicate runs were repeated on two different occasions as a measure of reproducibility) and data were acquired using the MassLynx programs (version. 4.1, SCN833; waters) operated in resolution and positive polarity modes. ProteinLynx Global Server (PLGS) 2.2 and Progenesis QI for proteomics (Progenesis QIfp version 2.0.5387) (Nonlinear Dynamics/ waters) were used for all automated data processing and database searching. The generated peptide masses were searched against two-unified non-redundant databases (Uniprot/SwissProt human protein sequence database) using the PLGS 2.5 and Progenesis QIfp for protein identification (Waters).
Data analysis and informatics. Progenesis QI v.2.0.5387 for proteomics was used to process and search the data to accurately quantify and identify proteins that are significantly changing between sample groups. The human database containing thousands of reviewed non-redundant entries were downloaded from UniProt/Swiss-Prot and search algorithm was applied as previoudly described (18) . The criteria used for the database search were as previously described (16) . Normalized label-free quantification was achieved using Progenesis QI software. The generated differentially expressed data was filtered to show only statistically (ANOVA), significantly regulated proteins (P≤0.05) and a fold change >1.5. In addition, 'Hi3' absolute quantification was performed using ADh as an internal standard to give an absolute amount of each identified protein. These options are available as incorporated into the Progenesis QIfp (Nonlinear Dynamics/Waters).
Results
Changes in protein expression between patients with/without major molecular response at 6 months. A total of 73 protein spots on 2-DE gels differed significantly between patients that achieved MMR from those who did not achieve MMR (P<0.05 and at least 1.5-fold difference). The locations of these protein spots are shown as marked on a representative 2-DE map derived from a sample with MMR in Fig. 2A . Even though the identifications of these protein spots were not done, their quantitative expression fingerprints from 2-DE analysis pattern accurately predicts 13 individuals that achieved MMR at 6 months from 12 subjects without MMR (No-MMR) using principal component analysis (PCA) (Fig. 2B) .
These findings are similar to what was observed with PCA plot generated from non-gel LC/MS/MS analysis platform, as some of the results were independently validated using the label free quantitative liquid chromatography tandem mass spectrometry as detailed below. (Fig. 3) .
LC/MS/MS
Evaluation of bone marrow and peripheral blood protein profiles for prognostic monitoring of prolonged and sustained treatment response vs. persistent no-major molecular response. Some of the patients have been followed for more than 24 months. Patients who have been consistent over a long-term in achieving and maintaining MMR from 6 months until 24 months were labeled as LT-MMR, while patients that have been persistent with No-MMR from 6 months until 24 months were called P-No-MMR. we believe that the ability to select early responders from 6 months all through 24 months would be very helpful to identify markers that would accurately predict patients with risk of delayed or suboptimal response further than 6 months. These cohorts of patients were considered as important in an effort to provide the possibility to identify surrogate biomarkers to evaluate long-term treatment response and discovery of disease-specific/disease-associated proteins for objective prognostic monitoring of CML patients.
Equal amounts of total peripheral blood plasma proteins from 10 LT-MMR patients were pooled and compared for their protein expressions among 10 other samples from P-No-MMR Table II). patients using quantitative label-free LC/MS/MS expression proteome analysis.
Approximately 700 proteins representing 280 unique protein species were identified (due to different protein isoforms). Only 164 of the 280 proteins were significantly differentially expressed between LT-MMR and P-No-MMR sample groups (>1.5-to ∞-fold change; P<0.05) and accurately predict patients with major molecular response (LT-MMR) vs. No-major molecular response (P-No-MMR) using unsupervised principal component analysis (Fig. 4A) . The list of identified differentially expressed proteins in PBP is described in Table IIA. Similar to peripheral blood samples, >700 proteins representing 250 unique protein species were identified when similar analysis was done on bone marrow pooled samples from 8 LT-MMR patients and 8 P-No-MMR patients. One hundred and thirty-eight of the total identified proteins were significantly differentially expressed between LT-MMR and P-No-MMR bone marrow sample groups (>1.5-to ∞-fold change, P<0.05; Table IIB ). These proteins predict accurately e. the expression of 138 identified bone marrow proteins that were significantly differentially expressed (>1.5-to ∞-fold change; P<0.05) between LT-MMR and P-No-MMR sample groups) separate all four sample groups including patients that stays on TKI after 1 year of imatinib Rx from patients ultimately requiring alternative treatment using principal component analysis. Long-term major molecular response (LT-MMR, blue), persistently no-major molecular response (P-No-MMR, purple, patients that stays on TKI after 1 year of imatinib Rx, green and patients ultimately requiring alternative treatment, red). The letters in grey color in the background represents the accession numbers of all the implicated proteins in the analysis.
[The image was generated using Progenesis QI for proteomics (Progenesis QIfp version 2.0.5387) (Nonlinear Dynamics/Waters)]. Some of the identified proteins were implicated in hematological diseases as potential biomarkers using ingenuity pathway analysis as detailed in LT-MMR patients vs. P-No-MMR patients using unsupervised principal component analysis (Fig. 4B) . These results were subsequently evaluated for comparisons with the patterns obtained in early treatment response at 6 months. Notably, the pattern and accuracy of clustering of samples is very similar to that observed with the hierarchical cluster analysis plots at 6 months (Fig. 3) .
Protein fingerprinting for prediction of treatment options for individualized therapy. Towards achieving the goal of personalized medicine, the above observed differentially expressed proteins between samples derived from LT-MMR patients vs. P-No-MMR patients were evaluated for their potential for objective prediction of treatment options for some of these cohorts of CML patients. Interestingly, the panel of 164 and 138 differentially expressed protein datasets derived from peripheral blood plasma (PBP) and bone marrow (BM) respectively, also discriminates patients that stay on IM after 1 year of treatment from patients that ultimately required alternative treatment options (second generation TKI/others) (Fig. 5) . Following >2 years of follow-up of these patients the same dataset of potential protein biomarkers could still accurately separate all analyzed sample groups into their respective molecular response and treatment sub groups, indicating their usefulness for treatment monitoring as well as prediction of best choice of therapy for individual patient. Some of the identified proteins were implicated in hematological diseases as potential biomarkers using ingenuity pathway analysis (IPA) (Fig. 6) . Functional annotations/ disease affiliations of some of these proteins implicated in CML are further described under discussion below.
Identification of protein changes in BM as a reflection of detectable changes in peripheral blood.
One of the main goals of this study was to identify/develop disease-specific/ disease-associated protein biomarkers seen in bone marrow tissue as well as in peripheral blood plasma. This would subsequently allow monitoring of such biomarker proteins in peripheral blood, rather than bone marrow, demanding less invasive procedures for objective prediction of individual's best treatment options and prognostic monitoring of CML patients. we therefore explored the possibility whether the proteins that are significantly differentially expressed in bone marrow do also show similar expression pattern in peripheral blood. with this in mind, we calculated how many of the 164 differentially expressed proteins in peripheral blood and the 138 protein dataset in bone marrow are common to both body compartments. we found that only 54 proteins (~35%) were in common between the two 164 and 138 datasets as described above. This set of 54 proteins was then subjected to unsupervised hierarchical clustering and correspondence analyses. As shown in Fig. 7 , all sample groups were distinctively separated into four response subtypes using unsupervised hierarchical cluster analysis. The common proteins between the two body fluid compartments were highlighted in bold in Table II .
Validation by western blot analysis of some of the identified proteins. In an attempt to validate some of the differentially expressed proteins, we have used immunoblotting analysis. Nine individual samples consisting of 4 samples not included in the proteomics analysis and 5 other samples from the proteomics analyzed sample groups were tested for their expression of haptoglobin and hemoglobin using specific antibodies against these proteins. The expression levels of these proteins across all sample groups were consistent with the average protein normalized levels seen with label-free quantitative LC/MS/MS analysis (Fig. 8) . Large scale validation of the majority of these proteins was beyond the scope of this study in order to develop limited panel of markers for clinical trial in a later study.
Discussion
Clinical and molecular diagnosis of most hematological malignancies including CML can be accurately made; however, prediction of treatment response elude the currently available tools for patient care. Unsupervised hierarchical cluster analysis of 54 identified differentially expressed proteins that are common in both bone marrow plasma (dataset of 138 proteins) and peripheral blood plasma (dataset of 164 proteins) of CML samples. The dendrogram shows correct prediction of patients with long-term major molecular response (LT-MMR, green), persistent no-major molecular response (P-No-MMR, blue), patients that stays on TKI after 1 year of imatinib Rx, purple and patients on alternative treatment outside TKI, red). The image was generated using J-Express Pro V 1.1 software program. (These 54 proteins used in generating this dendrogram plot are indicated with the letter a in Table II) .
A subset of significantly differentially expressed proteins from both peripheral blood and bone marrow were selected for their ability to discriminate samples derived from CML patients that responded differently to initial first line treatment with imatinib. Our strategy of proteomics mining of BM and PBP from the same individual patient would provide unique possibility to identify biomarkers from both sources thus, entailing less invasive procedures.
Report of microarray analysis of peripheral blood and bone marrow of CML samples in blast crisis cells, has been shown with demonstrable biological changes between two bodily fluids (19) . Our analysis of peripheral blood samples of 164 differentially expressed proteins show that all samples were correctly classified and similar result was observed with 138 protein changes in bone marrow samples as shown in Fig. 4 . Only 54 proteins were shown to be commonly differentially expressed between blood dataset and bone marrow protein dataset in the present study, supporting our notion that it might be possible to identify significant changes in the bone marrow of CML patients that are measurable at peripheral blood compartment for routine diagnostics.
we have attempted to use both the BMP and PBP datasets that accurately predict patients MMR status for possible prediction of patients that continue to stay on IM after 1 year of treatment vs. those that ultimately required alternative treatment options (second generation TKI/others). Thus, the expression of the 158 protein changes in BM between MMR and No-MMR were further evaluated in 16 unrelated patients that stay on TKI after 1 year of imatinib treatment from patients that ultimately required alternative treatment options (second generation TKI/others). We found four distinct clusters with samples with MMR and No-MMR being very closely separated (not as distinct as in Fig. 4) , while patients that stay on TKI (i.e. after 1 year of imatinib) treatment were distantly separated from patients that ultimately required alternative treatment options (second generation TKI/others) as shown in Fig. 5 , meaning that it will be challenging to construct a universal model for management of CML patients and that prognostic datasets need to be created for each specific response type.
we have used two independent proteomics analysis platforms in the present study. The expression profiles of 2-DE protein spots successfully discriminated two sample groups of CML patients with MMR and No-MMR. we recognized the inherent limitation of 2-DE based studies (20) (21) (22) hence, we have in addition used label-free quantitative protein expression using high definition liquid chromatography tandem mass spectrometry (LC/MS/MS) to extensively map the proteome of bone marrow as well as peripheral blood samples.
Previous studies have used multivariate statistical algorithms and artificial learning models to predict cancer prognosis and for grading different solid tumors (15, (23) (24) (25) (26) (27) (28) . The majority of these studies reported varying degrees of sensitivity and specificity based on evaluation of different clinical parameters (20, 24) .
Gene expression studies on hematological disease have been largely carried out by analysis of DNA or RNA microarrays. These genomics studies have indicated the potentials of large scale analysis of gene expression towards better understanding the molecular basis of leukemogenesis and that this information could potentially be useful in the classification of subtypes of hematological malignancies (19, 29, 30) . In a recent study of CLL samples, Alsagaby and colleagues used combined transcriptomics and proteomics analyses to unravel the heterogeneity of gene expression patterns as well attempting to identify proteins that are implicated in prognosis of chronic lymphocytic leukemia (31) . Recent studies have attempted to evaluate protein changes between imatinib sensitive and resistance samples (32) as well as to better understand the molecular mechanism in therapy resistance at the level of bone marrow extracellular fluid in CML (33). Figure 8 . Western blots validation analysis abundance of 2 of the identified differentially expressed proteins. Each lane indicates the expression of 9 individual samples in each of the four sample groups representing long-term major molecular response to imatinib (LT-MMR), persistently no major molecular response (P-No-MMR), patients that stay on TKI after 1 year of imatinib treatment (On-TKI) and patients that ultimately required alternative treatment options, i.e. second generation TKI/others (Not-On-TKI). Albumin was used as internal standard for normalization. The histogram bars are the corresponding average group protein expressions of the two protein haptoglobin and hemoglobin using label-free LC/MS/MS expression analysis platform.
Our initial analysis of 64 differentially expressed proteins of peripheral blood for prognostic monitoring of early CML treatment response at 6 months was encouraging and led us into extensive analysis of samples with sustained long-term MMR against patients that persistently could not achieve MMR.
Some of the identified proteins in the bone marrow of the 138 dataset for the prolonged and sustained MMR vs. persistent No-MMR were further evaluated for their functional characteristics and their hematological disease relevance using ingenuity pathway analysis (IPA). In the canonical pathway analysis of network signaling of identified proteins, only 48 of the 138 identified differentially expressed proteins were represented in the IPA database. The analysis of the identified proteins is composed of multiple networks of which, one is implicated in hematological disorders. The cellular localization, interconnections and functional annotation as well as the expression profile of some of these 48 identified molecules are as detailed in Fig. 6A . A review of some of these molecules showed that they mostly regulate among others: cell-to-cell signaling and interaction, hematological system development and function, aggregation of blood cells, coagulation, as well as quantity of granulocytes as indicated in Fig. 6 . Among the identified proteins in this study is TYRO3 protein tyrosine kinase, a member of TAM family of receptor tyrosine kinases (RTKs) and known for their role as regulator of cellular proliferation, migration and survival processes, as well as maintenance of blood coagulation equilibrium (34) . we observed connection of TYRO 3 in AKT/P13K pathway; similar to that previously described (34) (35) (36) .
The S100A8 is a calcium-binding protein of the S100 family and have been described to be associated with myeloid differentiation (37). we observed a more than 9-fold differential expression of S100A8 and in the network connecting with RAS, TGFb, MAPK and MMP. The S-100 protein has been previously reported as a useful marker in juvenile chronic myeloid leukemia (JCML) as well as myeloid leukemia cutis (LC) (38, 39) .
Overexpression of MYC has been associated with CML with poor response to imatinib (40, 41) . we observed a more than 25-fold differential expression of MYC associated factor x in this study.
Altogether our findings indicate that rather than the use of a single marker, analyses of a panel of protein markers have the potential to provide better insight into complex biologic processes towards better prognostication of CML patients.
we recognize the limitation of this study as samples were prospectively collected and patients observed over the years for their treatment responses. One other issue with this study is the low number of patients enrolled in different clinical and molecular response groups; hence we have limited the analysis to evaluation of patients based on MMR and whether or not they are on IM or alternative treatment option (second generation TKI/others).
In conclusion, we have identified protein signatures capable of prediction of molecular response and choice of therapy for CML patients at 6 months and beyond using expression proteomics as objective stratification of CML patients for treatment options.
Although these results are very promising, we recognized that analysis of much larger materials of patients with similar treatments and responses will be necessary to validate if clustering analysis can be used as a routine prognostic tool for CML patients.
These proteins might be valuable once validated, to complement the currently existing parameters for reliable and objective prediction of disease progression, monitoring treatment response and clinical outcome of CML patients as a model of personalized medicine.
